An improved method for generating retroviral producer clones for vectors lacking a selectable marker gene

Blood Cells, Molecules and Diseases

Volumn 24, Issue 2, 1998, Pages 167-182

  Persons, Derek A ^a   Mehaffey, Michele G ^b   Kaleko, Michael ^b   Nienhuis, Arthur W ^a   Vanin, Elio F ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Retroviral producer cells; Retroviral vectors; Selectable marker gene

Indexed keywords

VIRUS VECTOR;

ARTICLE; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MARKER GENE; PRIORITY JOURNAL; TARGET CELL;

EID: 0032104669     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1006/bcmd.1998.0184     Document Type: Article

References (46)

1. 1. Miller AD. Retroviral vectors. Curr Top Mic Immunol 158:1-24, 1992.
2. 2. Nienhuis AW, Walsh CE, Liu, J. Virus as therapeutic gene transfer vectors. In: Young N.S., ed. Viruses and Bone Marrow, New York:Marcell Dekker, Inc. pp 353-414, 1993.
3. 3. Von Melchner H, Housman DE. The expression of neomycin phosphotransferase in human promyelocytic leukemia cells (HL60) delays their differentiation. Oncogene 2:131-140, 1987.
4. 4. Valera A, Perales JC, Hatzoglou M, Bosch F. Expression of the neomycin-resistance (neo) gene induces alterations in gene expression and metabolism. Hum Gene Ther 5:449-456, 1994.
5. 5. Kohn DB, Weinberg KI, Nolta JA, et al. Engraftment of gene-modified umbilical cord blood in neonates with adenosine deaminase deficiency. Nature Med 1:1017-1023, 1995.
6. 6. Brenner MK, Heslop HE, Rill D, et al. Gene Transfer and Bone Marrow Transplantation. Cold Spring Harbor Symp Quant Biol LIX:691-697, 1994.
7. + progenitors to sustain long-term hematopoiesis in immune-deficient mice after ex vivo retroviral-mediated transduction. Blood 89:446-456, 1997.
8. 8. Dunbar CE, Seidel NE, Doren S, et al. Improved retroviral gene transfer into murine and Rhesus peripheral blood or bone marrow repopulating cell primed in vivo with stem cell factor and granulocyte colony-stimulating factor. Proc Natl Acad Sci USA 93:11871-11876, 1996.
9. 9. Riddell SR, Elliott M, Lewinsohn DA, et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nature Med 2:216-223, 1996.
10. 10. Bonini C, Verzeletti S, Servida P, et al. Immunity against the transgene product may limit efficacy of HSV-TK-transduced donor peripheral blood lymphocytes after allo-BMT. Blood 86:628 (abstract), 1995.
11. 11. Krall WJ, Skelton DC, Yu XJ, et al. Increased levels of spliced RNA account for augmented expression from the MFG retroviral vector in hematopoietic cells. Gene Ther 3:37-48, 1996.
12. 12. Ohashi T, Boggs S, Robbins P, et al. Efficient transfer and sustained high expression of the human glucocerebrosidase gene in mice and their functional macrophages following transplantation of bone marrow transduced by a retroviral vector. Proc Natl Acad Sci USA 89:11332-11336, 1992.
13. + bone marrow cells. Blood 82:1975-1980, 1993.
14. 14. Correll PH, Colilla S, Dave HPG, Karlsson S. High levels of human glucocerebrosidase activity in macrophages of long-term reconstituted mice after retroviral infection of hematopoietic stem cells. Blood 80:331-336, 1992.
15. 15. Riviere I, Brose K, Mulligan RC. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci USA 92:6733-6737, 1995.
16. 16. Hwang SL, Gilboa E. Expression of genes introduced into cells by retroviral infection is more efficient than that of genes introduced by DNA transfection. J Virol 50:417-424, 1984.
17. 17. Murdoch B, Pereira DS, Wu X, Dick JE, Ellis J. A rapid screening procedure for the identification of high titer retrovirus packaging clones. Gene Ther 4:744-749, 1997.
18. 18. Onodera M, Yachie A, Nelson DM, Welchlin H, Morgan RA, Blaese RM. A simple and reliable method for screening retroviral producer clones without selectable markers. Hum Gene Ther 8:1189-1194, 1997.
19. 19. McLachlin JR, Mittereder N, Daucher MB, Kadan M, Eglitis MA. Factors affecting retroviral vector function and structural integrity. Virology 195:1-5, 1993.
20. 20. Hanenberg H, Xiao XL, Dilloo D, Hashino K, Kato I, Williams DA. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nature 2:876-882, 1996.
21. 21. Landau NR, Littman DR. Packaging system for rapid production of murine leukemia virus vectors with variable tropism. J Virol 66:5110-5113, 1992.
22. 22. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 90:8392-8396, 1993.
23. 23. Brenner MK, Rill DR, Holladay MS, et al. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet 342:1134-1137, 1993.
24. 24. Brenner MK, Rill DR, Moen RC, et al. Gene marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 341:85-86, 1993.
25. 25. Heslop HE, Brenner MK, Rooney C, et al. Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypic similar unrelated donor marrow grafts. Hum Gene Ther 5:381-397, 1994.
26. 26. Miller AD, Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 6:2895-2902, 1986.
27. 27. Danos O, Mulligan RC. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci USA 85:6460-6464, 1988.
28. 28. Sandelain M, Wang CH, Antoniou M, Grosveld F, Mulligan RC. Generation of a high-titer retroviral vector capable of expressing high levels of the human β-globin gene. Proc Natl Acad Sci USA 92:6728-6732, 1995.
29. 29. Huszar D, Ellis J, Bernstein A. A rapid and accurate method for determining the titer of a retrovirus lacking a selectable marker. Technique J Meth Cell Mol Biol 1:28-32, 1989.
30. 30. Parente MK, Wolfe JH. Production of increased titer retrovirus vectors from stable producer cell lines by superinfection and concentration. Gene Ther 3:756-760, 1996.
31. 31. Xu L, Stahl SK, Dave HP, et al. Correction of the enzyme deficiency in hematopoietic cells of Gaucher patients using a clinically acceptable retroviral supernatant transduction protocol. Exp Hematol 22:223-230, 1994.
32. 32. Bodine DM, McDonagh KT, Brandt SJ, et al. Development of a high-titer retrovirus producer cell line capable of gene transfer into rhesus monkey hematopoietic stem cells. Proc Natl Acad Sci USA 87:3738-3742, 1990.
33. 33. Lynch CM, Miller AD. Production of high-titer helper virus-free retroviral vectors by cocultivation of packaging cells with different host ranges. J Virol 65:3887-3890, 1991.
34. 34. Bestwick RK, Kozak SL, Kabat D. Overcoming interference to retroviral superinfection results in amplified expression and transmission of cloned genes. Proc Natl Acad Sci USA 85:5404-5408, 1988.
35. 35. Otto E, Jones-Trower A, Vanin EF, et al. Characterization of a replication-competent retrovirus resulting from recombination of packaging and vector sequences. Hum Gene Ther 5:567-575, 1994.
36. 36. Markowitz D, Goff S, Bank A. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J Virol 62:1120-1124, 1988.
37. 37. Dubridge RB, Tang P, Hsia HC, Leong PM, Miller JH, Calos MP. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 7:379-387, 1987.
38. 38. Schleiss MR, Degnin CR, Geballe AP. Translational control of human cytomegalovirus GP48 expression. J Virol 65:6782-6789, 1991.
39. 39. Lusky M, Botchan M. Inhibition of SV40 replication in simian cells by specific pBR322 DNA sequences. Nature 293:79-81, 1981.
40. 40. Miller AD, Verma IM. Two base changes restore infectivity to a noninfectious molecular clone of moloney murine leukemia virus (pMLV-1). J Virol 49:214-222, 1984.
41. 41. Wigler M, Pellicer A, Silverstein S, Axel R, Urlaub G. DNA-mediated transfer of adenine phosphoribosyl-transferase locus into mammalian cells. Proc Natl Acad Sci USA 76:1373-1376, 1979.
42. 42. Cone RD, Mulligan RC. High efficiency gene transfer into mammalian cells: generation of helper-free recombinant retrovirus with broad host range. Proc Natl Acad Sci USA 81:6349-6353, 1984.
43. 43. Bertran J, Miller JL, Yang Y, et al. Recombinant adeno-associated virus-mediated high-efficiency, transient expression of the murine cationic amino acid transporter (ecotropic retroviral receptor) permits stable transduction of human HeLa cells by ecotropic retroviral vectors. J Virol 70:6759-6766, 1996.
44. 44. Evans LH, Morrison RP, Malik FG, Portis J, Britt WJ. A neutralizable epitope common to the envelope glycoproteins of ecotropic, polytropic, xenotropic, and amphotropic murine leukemia viruses. J Virol 64:6176-6183, 1990.
45. 45. Yang Y, Vanin EF, Whitt M, et al. Inducible, high-level production of infectious murine leukemia retroviral vector particles pseudotyped with vesicular stomatitis virus G envelope protein. Hum Gene Ther 6:1203-1213, 1995.
46. 46. Persons DA, Allay JA, Allay ER, et al. Retroviral-mediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced progenitors in vitro and identification of genetically-modified cells in vivo. Blood 90:777-1786, 1997.